The Portuguese Biovance Capital led an €11 million investment round in the Spanish company Vaxdyn, specialized in vaccine development.
Vaxdyn is headquartered in Seville, Spain, and is focused on the research and development of immunological solutions in the healthcare sector.
The €11 million investment will allow the Spanish company to advance the development of vaccines targeting bacteria that are considered highly pathogenic and resistant to antibiotics.
This funding round represents a significant boost for vaccine research against resistant microorganisms, a growing global problem in the healthcare sector.



